Institution
Sunovion
Company•London, United Kingdom•
About: Sunovion is a company organization based out in London, United Kingdom. It is known for research contribution in the topics: Lurasidone & Placebo. The organization has 572 authors who have published 1022 publications receiving 18488 citations. The organization is also known as: Sunovion Pharmaceuticals, Inc..
Topics: Lurasidone, Placebo, Population, Eszopiclone, Atypical antipsychotic
Papers published on a yearly basis
Papers
More filters
Patent•
14 Jan 2004TL;DR: In this paper, the authors used optically pure (−) Pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazoles.
Abstract: Methods and compositions are disclosed utilizing optically pure (−) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Pantoprazole is an inhibitor of H + release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
3 citations
TL;DR: It is suggested that baseline CRP level combined with measures of metabolic risk significantly moderated the improvement in cognitive performance associated with lurasidone 160 mg/day treatment, underscoring the importance of maintaining a low metabolic risk profile in patients with schizophrenia.
3 citations
TL;DR: In this article, a ring opening cross-metathesis (ROM) of bicyclic alkenes with terminal aryl-alkenes on solid support was accomplished, with electron rich styrenes.
Abstract: Ring opening cross-metathesis (ROM) of bicyclic alkenes with terminal aryl alkenes on solid support was accomplished. A select group of resin-bound bicyclic alkenes underwent highly regioselective ROM with electron rich styrenes. The influence of both electronic and steric factors on regioselectivity was examined.
3 citations
TL;DR: Assessing health status along with lung function seems to provide additional information regarding the effectiveness of COPD maintenance treatments, and arformoterol-treated patients had greater improvements in health status than patients receiving placebo.
3 citations
Patent•
27 Nov 2000TL;DR: In this paper, methods and compositions employing norastemizole and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof, are presented.
Abstract: Methods and pharmaceutical compositions employing norastemizole and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof. Also included are methods and compositions employing norastemizole and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof.
3 citations
Authors
Showing all 572 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Chris H. Senanayake | 58 | 588 | 12142 |
| Paul J. Reider | 55 | 344 | 9827 |
| Antony Loebel | 42 | 223 | 6906 |
| Kenneth S. Koblan | 40 | 96 | 4380 |
| Richard G. Ball | 37 | 142 | 3684 |
| Robert D. Larsen | 36 | 147 | 3544 |
| Robert Goldman | 35 | 110 | 7064 |
| Raymond L. Woosley | 34 | 115 | 3811 |
| Rudy Schreiber | 33 | 80 | 3793 |
| Thomas R. Verhoeven | 29 | 127 | 3135 |
| Andrei Pikalov | 28 | 120 | 2583 |
| David Blum | 27 | 89 | 2958 |
| Mark A. Varney | 26 | 41 | 4032 |
| Lisa DiMichele | 25 | 88 | 1755 |
| John P. Hanrahan | 25 | 46 | 2781 |